Cibus, Inc. Class A (CBUS)

Over the past six months, Cibus's stock has experienced volatility. In March 2026, Cibus announced a public offering of Class A shares at $2.15 per share, aiming to raise approximately $15 million, leading to a premarket stock price drop. Cibus reported Q4 2025 results in March 2026, highlighting progress in its Rice program, regulatory momentum, and commercialization milestones, but the stock reacted negatively. Cibus reported Q3 2025 results with positive sentiment, noting Rice deals, regulatory wins, and a focus on cost reduction. On April 10, 2026, Cibus appointed Thomas Urban to its board. As of April 11, 2026, the stock's 52-week range was $1.09 to $4.19, and short interest in Cibus recently increased, indicating decreasing investor sentiment.

The agricultural industry is highly seasonal, leading to fluctuations in Cibus's sales and operating results. Cibus's revenues depend on trait royalties from seed sales, indirectly tied to growing and harvesting seasons. Adverse weather conditions, crop diseases, and pests can impact seed quality, volume, and cost, affecting royalty payments to Cibus. Climate change may further exacerbate these unpredictable shifts.

Cibus, Inc., an agricultural biotechnology company based in San Diego, California, specializes in precision gene editing for agricultural applications. Cibus develops and licenses gene-edited plant traits to seed companies, focusing on improving crop yields and reducing the need for chemicals, offering sustainable ingredients. The company's Rapid Trait Development System (RTDS), or "Trait Machine," makes precise changes to a plant's genetics without foreign DNA. Cibus collaborates with seed companies to advance commercial trait pipelines, improve crop traits, and develop specific crop applications. Cibus is also developing biofragrance products.

Cibus serves customers and partners across North America and Europe, with its headquarters and R&D facilities in San Diego, California. The company has expanded its global presence through strategic alliances, offering solutions to support sustainable agriculture. Cibus is pursuing commercialization strategies for its herbicide-tolerant rice traits in Latin America and the USA, with plans to expand customer relationships in India. The company has also participated in field testing and regulatory review processes in the UK.

Cibus's brand reputation has been impacted by a class-action lawsuit initiated in June 2024 following a report by Bonitas Research alleging issues with Cibus' gene-editing technology, causing a stock price drop. Despite this, Cibus's "Trait Machine" process was recognized by Fast Company Magazine as one of the most innovative products. The company also highlights its role in shaping the global regulatory framework for gene editing.

The ownership structure of Cibus stock includes institutional, retail, and individual investors. Institutional investors own approximately 10.48% to 19.1% of the company's stock, with major holders including Fmr Llc and Vanguard Group Inc. Insiders own approximately 30.02% of the stock, with Rory Riggs owning the most shares. Public companies and individual investors collectively own approximately 56.72% of the stock.